
ABEONA THERAPEUTICS INC.
100
Recent developments include Q3 2026 earnings reporting $13.5 million in net ZEVASKYN® revenue, acquisition of ABO-801, a Phase 3-ready candidate, and a $30 million private placement agreement. The company continues to expand its ZEVASKYN® qualified treatment center network and highlights FDA approval of FAYUVI™ gene therapy licensed to Ultragenyx.
- Abeona reported Q3 2026 net ZEVASKYN® revenue of $13.5 million and announced acquisition of ABO-801 from Ellodi Pharmaceuticals [N2].
- The company entered into a $30 million private placement agreement concurrent with the ABO-801 acquisition [N3].
- ZEVASKYN® commercialization momentum continues with expansion of qualified treatment centers and insurance coverage [N4][N5].
- FDA approval of FAYUVI™ gene therapy for MPS IIIA was highlighted; royalties depend on Ultragenyx’s commercialization [N6].
- Q3 2026 earnings call provided operational updates and financial results including net loss and EPS figures [N1].
Abeona Therapeutics Inc. develops and commercializes cell and gene therapies targeting rare genetic diseases with high unmet medical needs. The company’s flagship product, ZEVASKYN®, is an autologous gene-modified cellular sheet therapy approved by the FDA for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB), a severe genetic skin disorder. ZEVASKYN® is manufactured at Abeona’s Cleveland, Ohio facility and administered through a network of qualified treatment centers across the U.S. Abeona’s pipeline includes gene therapies for ophthalmic diseases such as X-linked Retinoschisis, Stargardt disease, and Autosomal Dominant Optic Atrophy, leveraging its proprietary AIM™ capsid technology platform. The company also licenses FAYUVI™, a gene therapy approved for Sanfilippo syndrome type A, to Ultragenyx, from which it receives royalties. Recent acquisitions include ABO-801, a Phase 3-ready candidate for eosinophilic esophagitis, expanding Abeona’s pipeline. The company reported Q3 2026 net ZEVASKYN® revenue of $13.5 million and maintains a strong liquidity position with over $66 million in cash and equivalents as of September 30, 2026.
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on cell and gene therapies for rare and life-threatening diseases. Its lead commercial product, ZEVASKYN®, is FDA-approved for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB) and is manufactured in-house at its Cleveland facility. The company has activated multiple qualified treatment centers and secured broad insurance coverage to support commercialization. Abeona's pipeline includes gene therapies for ophthalmic diseases using novel AIM™ capsids and recently acquired ABO-801, a Phase 3-ready candidate. Financially, as of September 30, 2026, the company reported $66.3 million in cash and equivalents, a strong liquidity position, and a net loss of $4.8 million for the quarter. Manufacturing complexities and clinical development risks for acquired candidates are notable challenges. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Abeona’s commercial launch of ZEVASKYN® for RDEB demonstrates initial revenue generation and expanding treatment center network, indicating growing market penetration in a rare disease with high unmet need. The company’s proprietary manufacturing capabilities and AIM™ capsid platform support pipeline advancement in ophthalmic gene therapies, potentially broadening its therapeutic portfolio. Recent acquisition of ABO-801 adds a Phase 3-ready candidate, enhancing pipeline diversity. FDA approval of FAYUVI™ licensed to Ultragenyx provides a royalty revenue stream. Strong liquidity and capital raises support ongoing development and commercialization efforts.
Manufacturing complexities and batch release challenges for ZEVASKYN® have caused delays and could continue to impact supply and commercialization. Clinical development risks for acquired candidates like ABO-801 include potential delays, regulatory hurdles, and uncertain trial outcomes given prior failed Phase 3 studies. Reliance on third parties for commercialization of licensed products such as FAYUVI™ exposes Abeona to risks outside its control, including sales performance and royalty payments. The company’s net losses and need for additional capital raise dilution and operational risks. Market adoption of novel gene therapies in rare diseases may face reimbursement and competitive challenges.
Abeona’s moat is anchored in its FDA-approved autologous cell-based gene therapy ZEVASKYN® for RDEB, a rare and debilitating genetic skin disease with no cure and limited treatment options. The product’s orphan drug and rare pediatric disease designations provide regulatory exclusivity and market advantages. The company’s proprietary manufacturing platform and cGMP facility in Cleveland enable in-house production of complex gene-modified cellular therapies, supporting quality control and supply reliability. Abeona’s AIM™ capsid technology platform for gene therapies targeting ophthalmic diseases represents a differentiated scientific approach with potential for broad application. The established network of qualified treatment centers trained to administer ZEVASKYN® and secured insurance coverage, including CMS reimbursement, further strengthen commercial positioning. Intellectual property protections on vector engineering, manufacturing processes, and clinical products contribute to competitive barriers.
• Manufacturing and Supply Risks: Complex manufacturing processes for ZEVASKYN® involve risks such as batch rejections due to sterility assay false positives and cellular identity test failures, which have caused delays in product launch and commercial supply.
• Clinical Development and Regulatory Risks: Acquired product candidate ABO-801 has a history of failed Phase 3 trials and may face delays or failure in obtaining regulatory approval, with uncertainties around clinical trial design and FDA acceptance of endpoints.
• Commercialization and Royalty Risks: Royalties from licensed product FAYUVI™ depend on Ultragenyx’s commercial performance and strategic priorities, which are outside Abeona’s control, potentially affecting revenue streams.
• Capital and Financial Risks: The company has reported net losses and may require additional capital through equity or debt financing, which could dilute existing shareholders and impose operational restrictions.
Business trends: Commercial launch of ZEVASKYN® progressing with revenue generation and treatment center expansion; pipeline growth through acquisitions and AIM™ capsid platform development.
Execution milestones: Scaling manufacturing capabilities, advancing clinical trials for pipeline candidates including ABO-801, and securing reimbursement and market access.
Key risks: Manufacturing complexities impacting supply, clinical and regulatory uncertainties for acquired candidates, reliance on third-party commercialization for licensed products, and capital raising needs.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for life-threatening diseases [S1].
- The company’s lead commercial product is ZEVASKYN®, an autologous cell-based gene therapy approved by the FDA on April 28, 2025, for treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB) [S1].
- ZEVASKYN® is the only FDA-approved product for RDEB wounds with a single surgical application and has orphan drug and rare pediatric disease designations [S1].
- ZEVASKYN® is manufactured at the company’s cGMP facility in Cleveland, Ohio, and treatments are administered through a network of qualified treatment centers with expertise in cell and gene therapy; as of March 2026, four such centers were activated [S1].
- The company began treating patients with ZEVASKYN® in Q4 2025 and has been expanding the qualified treatment center network [S1].
- ZEVASKYN® commercialization includes engagement with healthcare stakeholders and broad insurance coverage including CMS and Medicaid across all US states and Puerto Rico; a permanent CMS J-code was issued effective January 1, 2026 [S1].
- The company’s pipeline includes gene therapies for ophthalmic diseases using novel AIM™ capsids, including ABO-503 for X-linked Retinoschisis, ABO-504 for Stargardt disease, and ABO-505 for Autosomal Dominant Optic Atrophy, with preclinical and IND-enabling activities ongoing or planned [S1].
- Abeona acquired ABO-801 (formerly APT-1011), a Phase 3-ready drug candidate, on November 6, 2026, and entered into a $30 million private placement agreement [N3][N2][S2].
- The company reported Q3 2026 net ZEVASKYN® revenue of $13.5 million [N2].
- The FDA approved FAYUVI™ (rebisufligene etisparvovec-hopf) in September 2026, a gene therapy licensed to Ultragenyx for Sanfilippo syndrome type A (MPS IIIA); Abeona is eligible for royalties based on sales [S2][N6].
- Financial snapshot as of September 30, 2026, shows cash and equivalents of $66.3 million, current assets of $157.7 million, current liabilities of $27.7 million, a current ratio of 5.69, and a net loss of $4.8 million for the quarter; EPS basic and diluted were -$0.08 [S2].
- Manufacturing of ZEVASKYN® is complex with risks including batch rejections due to sterility assay false positives and cellular identity test issues; these have caused delays in launch and commercial supply [S4][S5].
- The company’s strategy includes commercializing ZEVASKYN®, advancing cell and gene therapy programs, leveraging internal manufacturing capabilities, and expanding the pipeline through in-licensing and partnerships [S1].
- Risks include potential delays and challenges in clinical development and regulatory approval of acquired candidates like ABO-801, manufacturing complexities, and reliance on third parties for commercialization of licensed products such as FAYUVI™ [S2].
Generated 2026-11-10
- N1
- N7
- S1 | 2026-03-17 | 10-K
- S2 | 2026-11-09 | 10-Q
- N1 | 2026-11-09 | www.nasdaq.com | Abeona Therapeutics (ABEO) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/abeona-therapeutics-abeo-q3-2026-earnings-call-transcript
- N2 | 2026-11-09 | www.nasdaq.com | Abeona Therapeutics Reports Q3 Net ZEVASKYN Revenue of $13.5 million and Acquisition of ABO-801 | https://www.nasdaq.com/articles/abeona-therapeutics-reports-q3-net-zevaskyn-revenue-135-million-and-acquisition-abo-801
- N3 | 2026-11-09 | www.nasdaq.com | Abeona Therapeutics Inc. Acquires Phase 3-Ready APT-1011 and Enters Into Agreement for $30 Million Private Placement | https://www.nasdaq.com/articles/abeona-therapeutics-inc-acquires-phase-3-ready-apt-1011-and-enters-agreement-30-million
- N4 | 2026-09-22 | www.nasdaq.com | Abeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. Wainwright | https://www.nasdaq.com/articles/abeona-therapeutics-highlights-zevaskyn-launch-momentum-revenue-growth-hc-wainwright
- N5 | 2026-09-22 | www.nasdaq.com | Abeona Expands ZEVASKYN Network as RDEB Launch Gains Momentum | https://www.nasdaq.com/articles/abeona-expands-zevaskyn-network-rdeb-launch-gains-momentum
- N6 | 2026-09-18 | www.nasdaq.com | Abeona Therapeutics (ABEO) Highlights FDA Approval Of FAYUVI Gene Therapy For MPS IIIA | https://www.nasdaq.com/articles/abeona-therapeutics-abeo-highlights-fda-approval-fayuvi-gene-therapy-mps-iiia
- N7 | 2026-08-20 | www.nasdaq.com | Abeona (ABEO) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/abeona-abeo-q2-2026-earnings-call-transcript
- N8 | 2026-08-13 | www.nasdaq.com | Abeona Therapeutics Q2 Earnings Call Highlights | https://www.nasdaq.com/articles/abeona-therapeutics-q2-earnings-call-highlights
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


